Search

Your search keyword '"Frakes, Jessica"' showing total 331 results
Start Over "Frakes, Jessica"
331 results on '"Frakes, Jessica"'

103. Abstract 4293: Final result of lenvatinib and capecitabine in combination with external beam radiation in treatment of locally advanced rectal cancer: Phase I clinical trial

Author

Tandon, Ankita, primary, Frakes, Jessica M., additional, Mehta, Rutika, additional, Hoffe, Sarah, additional, Imanirad, Iman, additional, Jimenez, Maria E. Martinez, additional, Sanchez, Julian, additional, Malafa, Mokenge, additional, Felder, Seth, additional, Dessureault, Sophie, additional, and Kim, Richard D., additional

Published
2020
Full Text
View/download PDF

105. Phase I study of NBTXR3 activated by radiotherapy in patients with advanced cancers treated with an anti-PD-1 therapy.

Author

Shen, Colette, primary, Frakes, Jessica, additional, Weiss, Jared, additional, Caudell, Jimmy J., additional, Hackman, Trevor G, additional, Akulian, Jason A., additional, El-Haddad, Ghassan, additional, Hu, Yun, additional, Dixon, Robert, additional, Pearson, Alexander T., additional, Barsoumian, Hampartsoum B., additional, Cortez, Maria Angelica, additional, Jameson, Katherine LaRoque, additional, Said, Patricia, additional, Welsh, James William, additional, and Seiwert, Tanguy Y., additional

Published
2020
Full Text
View/download PDF

106. Predictors of recurrence and implications for overall survival in borderline resectable pancreatic cancer patients treated with total neoadjuvant therapy: A retrospective cohort study.

Author

Kaplan, Jori Lee, primary, Powers, Benjamin, additional, Fan, Wenyi, additional, Schell, Michael J., additional, Centeno, Barbara, additional, Kim, Dae Won, additional, Frakes, Jessica, additional, Hoffe, Sarah E., additional, Malafa, Mokenge Peter, additional, Hodul, Pamela Joy, additional, Fleming, Jason B., additional, and Carballido, Estrella M., additional

Published
2020
Full Text
View/download PDF

107. Adaptive dose optimization trial of stereotactic body radiation therapy (SBRT) with or without GC4419 (avasopasem manganese) in pancreatic cancer.

Author

Moser, Elizabeth Charlotte, primary, Hoffe, Sarah E., additional, Frakes, Jessica, additional, Aguilera, Todd Anthony, additional, Karim, Mona, additional, Colbert, Lauren Elizabeth, additional, Moningi, Shalini, additional, Tzeng, Ching-Wei David, additional, Thall, Peter F., additional, Pant, Shubham, additional, Bhutani, Manoop S., additional, Brookes, Melissa, additional, Holmlund, Jon, additional, Herman, Joseph M., additional, and Taniguchi, Cullen M., additional

Published
2020
Full Text
View/download PDF

108. CT‐based radiomic features to predict pathological response in rectal cancer: A retrospective cohort study

Author

Yuan, Zhigang, primary, Frazer, Marissa, additional, Zhang, Geoffrey G, additional, Latifi, Kujtim, additional, Moros, Eduardo G, additional, Feygelman, Vladimir, additional, Felder, Seth, additional, Sanchez, Julian, additional, Dessureault, Sophie, additional, Imanirad, Iman, additional, Kim, Richard D, additional, Harrison, Louis B, additional, Hoffe, Sarah E, additional, and Frakes, Jessica M, additional

Published
2020
Full Text
View/download PDF

111. Phase I study of preoperative capecitabine and lenvatinib with external radiation therapy in locally advanced rectal adenocarcinoma.

Author

Tandon, Ankita, primary, Frakes, Jessica, additional, Mehta, Rutika, additional, Hoffe, Sarah E., additional, Martinez Jimenez, Maria E, additional, Imanirad, Iman, additional, Sanchez, Julian, additional, Malafa, Mokenge Peter, additional, Felder, Seth, additional, Dessureault, Sophie, additional, and Kim, Richard D., additional

Published
2020
Full Text
View/download PDF

113. Clinical factors associated with the development of postoperative atrial fibrillation in esophageal cancer patients receiving multimodality therapy before surgery

Author

Song, Ethan Y., primary, Venkat, Puja, additional, Fradley, Michael, additional, Frakes, Jessica M., additional, Klocksieben, Farina, additional, Fontaine, Jacques, additional, Mehta, Rutika, additional, Saeed, Sabrina, additional, Hoffe, Sarah E., additional, and Pimiento, Jose M., additional

Published
2020
Full Text
View/download PDF

114. Superficial and peripheral dose in compensator‐based FFF beam IMRT

Author

Zhang, Daniel G., Feygelman, Vladimir, Moros, Eduardo G., Latifi, Kujtim, Hoffe, Sarah, Frakes, Jessica, and Zhang, Geoffrey G.

Subjects
Phantoms, Imaging, 87.55.Gh, Radiotherapy Planning, Computer-Assisted, 87.55.km, Radiotherapy Dosage, Equipment Design, superficial dose, Neoplasms, Radiation Oncology Physics, Humans, Scattering, Radiation, Radiotherapy, Intensity-Modulated, Particle Accelerators, compensator‐based IMRT, 87.53.Bn, Monte Carlo, Monte Carlo Method, flattening filter‐free, Filtration
Abstract

Flattening filter‐free (FFF) beams produce higher dose rates. Combined with compensator‐based intensity modulated radiotherapy (IMRT) techniques, the dose delivery for each beam can be much shorter compared to the flattened beam MLC‐based or flattened beam compensator‐based IMRT. This ‘snap shot’ IMRT delivery is beneficial to patients for tumor motion management. Due to softer energy, superficial doses in FFF beam treatment are usually higher than those from flattened beams. Due to no flattening filter, thus less photon scattering, peripheral doses are usually lower in FFF beam treatment. However, in compensator‐based IMRT using FFF beams, the compensator is in the beam pathway. Does it introduce beam hardening effects and scattering such that the superficial dose is lower and peripheral dose is higher compared to FFF beam MLC‐based IMRT? This study applied Monte Carlo techniques to investigate the superficial and peripheral doses in compensator‐based IMRT using FFF beams and compared it to the MLC‐based IMRT using FFF beams and flattened beams. Besides varying thicknesses of brass slabs to simulate varying thicknesses of compensators, a simple cone‐shaped compensator was simulated to mimic a clinical application. The dose distribution in water phantom by the cone‐shaped compensator was then simulated by multiple MLC‐defined FFF and flattened beams with varying apertures. After normalization to the maximum dose, Dmax, the superficial and peripheral doses were compared between the FFF beam compensator‐based IMRT and FFF/flattened beam MLC‐based IMRT. The superficial dose at the central 0.5 mm depth was about 1% (of Dmax) lower in the compensator‐based 6 MV FFF (6FFF) IMRT compared to the MLC‐based 6FFF IMRT, and about 8% higher than the flattened 6 MV MLC‐based IMRT dose. At 8 cm off‐axis at depth of central maximum dose, dmax, the peripheral dose between the 6FFF and flattened 6 MV MLC demonstrated similar doses, while the compensator dose was about 1% (of Dmax) higher. Compensators reduce the superficial doses slightly compared to open FFF beams, but increases the peripheral doses due to scatter in the compensator.

Published
2016

115. Impact of histology classification on pathologic treatment response and overall survival in distal esophageal cancer patients: a propensity matched analysis.

Author

Saeed, Sabrina M, Naffouje, Samer, Mehta, Rutika, Hoffe, Sarah E, Fontaine, Jacques P, Lauwers, Gregory Y, Shah, Parth, Frakes, Jessica, and Pimiento, Jose M

Subjects
OVERALL survival, HISTOLOGY, CANCER patients, SURVIVAL rate, RECTAL cancer, ESOPHAGEAL cancer, SQUAMOUS cell carcinoma
Abstract

Background Esophageal squamous cell carcinoma (ESCC) has been linked to superior pathologic treatment response compared to esophageal adenocarcinoma (EAC) after neoadjuvant chemoradiation. However, the impact of histology on survival remains unclear. It has been suggested, based on epidemiologic similarities, that distal EAC should be grouped with gastric cancers as an entity distinct from distal ESCC, but there is little data to support this recommendation. We therefore aim to compare pathologic treatment response (PTR) and overall survival (OS) in patients with distal EAC versus distal ESCC. Methods This retrospective cohort study included patients who underwent esophagectomy for distal esophageal malignancy. Histologic sub-groups were matched (1:1) using a propensity-score matching approach. Pre-operative clinical parameters, oncologic outcomes and survival were compared between groups. Results 1031 distal EC patients, with a median age of 64.4 years and a male preponderance (86.5%), underwent esophagectomy at our institution between 1999 and 2019. 939 (91.1%) patients had a diagnosis of EAC and 92 (8.9%) had ESCC. A higher proportion of ESCC patients were female (26.1% vs. 12.1%; P  < 0.01) and non-white (12.0% vs. 3.8%; P  < 0.01). Propensity-score sub-analysis identified 75 matched pairs. Rates of pathologic complete response (58.0% vs. 48.9%; P  = 0.67) and OS (43.0 vs. 52.0 months; P  = 0.808) were not significantly different between matched groups. Conclusions Although traditionally known to have a better overall PTR compared to EAC, ESCC patients in our large series did not show any improvement in PTR or OS. Treatment recommendations for patients with EAC and ESCC should consider tumor location in addition to histology. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

118. Tu1336 COMPARISON OF TRADITIONAL BACK-LOADED FIDUCIAL NEEDLES WITH PRELOADED FIDUCIAL NEEDLES IN EUS-GUIDED FIDUCIAL MARKER PLACEMENT FOR IMAGE-GUIDED RADIATION THERAPY (IGRT) IN PATIENTS WITH PANCREATIC ADENOCARCINOMA (PC): A RANDOMIZED CONTROLLED TRIAL (RCT)

Author

Machicado, Jorge D., primary, Obuch, Joshua C., additional, Goodman, Karyn, additional, Schefter, Tracey, additional, Frakes, Jessica, additional, Hoffe, Sarah, additional, Latifi, Kujtim, additional, Simon, Violette C., additional, Santangelo, Tess, additional, Ezekwe, Ezenwanyi, additional, Edmundowicz, Steven A., additional, Brauer, Brian C., additional, Shah, Raj J., additional, Hammad, Hazem T., additional, Wagh, Mihir S., additional, Attwell, Augustin, additional, Han, Samuel, additional, Klapman, Jason B., additional, and Wani, Sachin B., additional

Published
2019
Full Text
View/download PDF

119. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis

Author

Janssen, Quisette P, primary, Buettner, Stefan, additional, Suker, Mustafa, additional, Beumer, Berend R, additional, Addeo, Pietro, additional, Bachellier, Philippe, additional, Bahary, Nathan, additional, Bekaii-Saab, Tanios, additional, Bali, Maria A, additional, Besselink, Marc G, additional, Boone, Brian A, additional, Chau, Ian, additional, Clarke, Stephen, additional, Dillhoff, Mary, additional, El-Rayes, Bassel F, additional, Frakes, Jessica M, additional, Grose, Derek, additional, Hosein, Peter J, additional, Jamieson, Nigel B, additional, Javed, Ammar A, additional, Khan, Khurum, additional, Kim, Kyu-Pyo, additional, Kim, Song Cheol, additional, Kim, Sunhee S, additional, Ko, Andrew H, additional, Lacy, Jill, additional, Margonis, Georgios A, additional, McCarter, Martin D, additional, McKay, Colin J, additional, Mellon, Eric A, additional, Moorcraft, Sing Yu, additional, Okada, Ken-Ichi, additional, Paniccia, Alessandro, additional, Parikh, Parag J, additional, Peters, Niek A, additional, Rabl, Hans, additional, Samra, Jaswinder, additional, Tinchon, Christoph, additional, van Tienhoven, Geertjan, additional, van Veldhuisen, Eran, additional, Wang-Gillam, Andrea, additional, Weiss, Matthew J, additional, Wilmink, Johanna W, additional, Yamaue, Hiroki, additional, Homs, Marjolein Y V, additional, van Eijck, Casper H J, additional, Katz, Matthew H G, additional, and Groot Koerkamp, Bas, additional

Published
2019
Full Text
View/download PDF

120. Novel Genomic-Based Strategies to Personalize Lymph Node Radiation Therapy

Author

Oliver, Daniel E., primary, Mohammadi, Homan, additional, Figura, Nicholas, additional, Frakes, Jessica M., additional, Yamoah, Kosj, additional, Perez, Bradford A., additional, Wuthrick, Evan J., additional, Naghavi, Arash O., additional, Caudell, Jimmy J., additional, Harrison, Louis B., additional, Torres-Roca, Javier F., additional, and Ahmed, Kamran A., additional

Published
2019
Full Text
View/download PDF

122. Integrated profiling the patterns of pathologic response to neoadjuvant chemoradiation and the genomic-based radiation sensitivity in rectal cancer.

Author

Yuan, Zhigang, primary, Ahmed, Kamran A., additional, Naqvi, Syeda Mahrukh Hussnain, additional, Schell, Michael J., additional, Felder, Seth, additional, Sanchez, Julian, additional, Dessureault, Sophie, additional, Imanirad, Iman, additional, Kim, Richard D., additional, Torres-Roca, Javier, additional, Hoffe, Sarah E., additional, and Frakes, Jessica, additional

Published
2019
Full Text
View/download PDF

129. Contributors 4th edition

Author

Caggiano, Allan, Naghavi, Arash, Sim, Austin, Rosenstein, Barry, Yildirim, Berna Akkus, Pehlivan, Berrin, Cai, Bin, Imber, Brandon, Zheng, Dandan, Tsang, Derek, Mondal, Dodul, Gujral, Dorothy, Sezen, Duygu, Yang, Eddy, Keit, Emily, Topkan, Erkan, Harada, Garrett, Yang, George, Cittolin Santos, Giordano, Yavas, Guler, Le, Hien, Bagshaw, Hilary, Michael Yu, Hsiang-Hsuan, Youssef, Irini, Harris, Jeremy, Jaboin, Jerry, Frakes, Jessica, Caudell, Jimmy, Leung, John, Paly, Jonathan, Salama, Joseph, Hong, Julian, Ahmed, Kamran, Kataki, Kaushik, Gifford, Kent, Freedman, Laura, Dong, Lei, Agarwal, Manuj, Buyyounouski, Mark, Williams, Matthew, Cummings, Michael, Campbell, Michael, Penniment, Michael, Cao, Minsong, Awan, Musaddiq, Taunk, Neil, Prionas, Nicolas, Durankus, Nilufer Kilic, Dona Lemus, Olga Maria, Karukonda, Pooja, Ger, Rachel, Parikh, Rahul, Kumar, Ritesh, Shen, Sui, Gill, Sukhdeep, Kim, Sungjune, Dziuk, Timothy, Selek, Ugur, Khatri, Vaseem, Bolukbasi, Yasemin, and Wu, Yufan Fred

Published
2024
Full Text
View/download PDF

130. Pretreatment CT and 18F‐FDG PET‐based radiomic model predicting pathological complete response and loco‐regional control following neoadjuvant chemoradiation in oesophageal cancer.

Author

Rishi, Anupam, Zhang, Geoffrey G, Yuan, Zhigang, Sim, Austin J, Song, Ethan Y, Moros, Eduardo G, Tomaszewski, Michal R, Latifi, Kujtim, Pimiento, Jose M, Fontaine, Jacques‐Pierre, Mehta, Rutika, Harrison, Louis B, Hoffe, Sjmiroh E, and Frakes, Jessica M

Subjects
COMPUTED tomography, POSITRON emission tomography, RADIOMICS, TREATMENT effectiveness, CHEMORADIOTHERAPY, WATER bottles, AIRBUS A320
Abstract

Introduction: To develop a radiomic‐based model to predict pathological complete response (pCR) and outcome following neoadjuvant chemoradiotherapy (NACRT) in oesophageal cancer. Methods: We analysed 68 patients with oesophageal cancer treated with NACRT followed by esophagectomy, who had staging 18F‐fluorodeoxyglucose (18F‐FDG) positron emission tomography (PET) and computed tomography (CT) scans performed at our institution. An in‐house data‐chjmirocterization algorithm was used to extract 3D‐radiomic features from the segmented primary disease. Prediction models were constructed and internally validated. Composite feature, Fc = α * FPET + (1 − α) * FCT, 0 ≤ α ≤ 1, was constructed for each corresponding CT and PET feature. Loco‐regional control (LRC), recurrence‐free survival (RFS), metastasis‐free survival (MFS) and overall survival (OS) were estimated by Kaplan–Meier analysis, and compared using log‐rank test. Results: Median follow‐up was 59 months. pCR was achieved in 34 (50%) patients. Five‐year RFS, LRC, MFS and OS were 67.1%, 88.5%, 75.6% and 57.6%, respectively. Tumour Regression Grade (TRG) 0–1 indicative of complete response or minimal residual disease was significantly associated with improved 5‐year LRC [93.7% vs 71.8%; P = 0.020; HR 0.19, 95% CI 0.04–0.85]. Four sepjmirote pCR predictive models were built for CT alone, PET alone, CT+PET and composite. CT, PET and CT+PET models had AUC 0.73 ± 0.08, 0.66 ± 0.08 and 0.77 ± 0.07, respectively. The composite model resulted in an improvement of pCR predicting power with AUC 0.87 ± 0.06. Stratifying patients with a low versus high radiomic score showed clinically relevant improvement in 5‐year LRC favouring low‐score group (91.1% vs. 80%, 95% CI 0.09–1.77, P = 0.2). Conclusion: The composite CT/PET radiomics model was highly predictive of pCR following NACRT. Validation in larger data sets is warranted to determine whether the model can predict clinical outcomes. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

131. Pretreatment CT and PET radiomics predicting rectal cancer patients in response to neoadjuvant chemoradiotherapy.

Author

Zhigang Yuan, Frazer, Marissa, Rishi, Anupam, Latifi, Kujtim, Tomaszewski, Michal R., Moros, Eduardo G., Feygelman, Vladimir, Felder, Seth, Sanchez, Julian, Dessureault, Sophie, Imanirad, Iman, Kim, Richard D., Harrison, Louis B., Hoffe, Sarah E., Zhang, Geoffrey G., and Frakes, Jessica M.

Abstract

Background: The purpose of this study was to characterize pre-treatment non-contrast computed tomography (CT) and 18F-fluorodeoxyglucose positron emission tomography (PET) based radiomics signatures predictive of pathological response and clinical outcomes in rectal cancer patients treated with neoadjuvant chemoradiotherapy (NACR T). Materials and methods: An exploratory analysis was performed using pre-treatment non-contrast CT and PET imaging dataset. The association of tumor regression grade (TRG) and neoadjuvant rectal (NAR) score with pre-treatment CT and PET features was assessed using machine learning algorithms. Three separate predictive models were built for composite features from CT + PET. Results: The patterns of pathological response were TRG 0 (n = 13; 19.7%), 1 (n = 34; 51.5%), 2 (n = 16; 24.2%), and 3 (n = 3; 4.5%). There were 20 (30.3%) patients with low, 22 (33.3%) with intermediate and 24 (36.4%) with high NAR scores. Three separate predictive models were built for composite features from CT + PET and analyzed separately for clinical endpoints. Composite features with α = 0.2 resulted in the best predictive power using logistic regression. For pathological response prediction, the signature resulted in 88.1% accuracy in predicting TRG 0 vs. TRG 1-3; 91% accuracy in predicting TRG 0-1 vs. TRG 2-3. For the surrogate of DFS and OS, it resulted in 67.7% accuracy in predicting low vs. intermediate vs. high NAR scores. Conclusion: The pre-treatment composite radiomics signatures were highly predictive of pathological response in rectal cancer treated with NACR T. A larger cohort is warranted for further validation. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

132. Is Preoperative G-Tube Use Safe for Esophageal Cancer Patients?

Author

Saeed, Sabrina M., Fontaine, Jacques P., Dam, Aamir N., Hoffe, Sarah E., Cameron, Miles, Frakes, Jessica, Mehta, Rutika, Gurd, Erin, and Pimiento, Jose M.

Abstract

Objective: Gastrostomy tubes (g-tubes) have been used with caution prior to esophageal resection due to the risks of inoculation metastasis and of injury to the gastric conduit used for reconstruction. In this study, we aim to evaluate the safety of preoperative g-tube placement by comparing outcomes in patients undergoing esophageal resection with and without prior g-tube use.Method: We retrospectively reviewed our institution's database of 1113 esophagectomies performed between 1994 and 2018. We included only patients who received neoadjuvant therapy and identified 65 patients who received preoperative nutritional support through a g-tube (GT+) and 657 who did not (GT-). Demographics, postoperative complications, survival, and cancer recurrence rates were compared between GT + and GT- using Chi-squared and Kaplan-Meier survival analyses.Results: Seven-hundred twenty-two patients (122 female, 600 male) with a median age of 63.2 (28.2-86.3) met our inclusion criteria. Between GT+ (n = 65) and GT- (n = 657), there were no significant differences in anastomotic leak rates (11.5% vs 10.9%; p = 0.901), postoperative mortality (3.1% vs 3.9%; p = 0.765), or overall complications (63.1% vs 65.1%; p = 0.746). GT + was associated with a significantly lower overall survival compared to GT- (32.5 m vs 92.9 m; p = 0.003), and tumor recurrence rates were similar (30.6% vs 31.8%; p = 0.851). There were no cases documenting damage to the gastric conduit caused by prior g-tube placement.Conclusions: G-tube usage was not associated with increased tumor recurrence, anastomotic leak rates, or overall complication rates in this study. Our data suggest that g-tube usage is safe for patients with esophageal cancer requiring preoperative nutrition. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

137. Patient choice for high-volume center radiation impacts head and neck cancer outcome

Author

Naghavi, Arash O., primary, Echevarria, Michelle I., additional, Strom, Tobin J., additional, Abuodeh, Yazan A., additional, Venkat, Puja S., additional, Ahmed, Kamran A., additional, Demetriou, Stephanie, additional, Frakes, Jessica M., additional, Kim, Youngchul, additional, Kish, Julie A., additional, Russell, Jeffery S., additional, Otto, Kristen J., additional, Chung, Christine H., additional, Harrison, Louis B., additional, Trotti, Andy, additional, and Caudell, Jimmy J., additional

Published
2018
Full Text
View/download PDF

139. Viral hepatitis associated hepatocellular carcinoma outcomes with yttrium-90 radioembolization

Author

Frakes, Jessica M., primary, Abuodeh, Yazan A., additional, Naghavi, Arash O., additional, Echevarria, Michelle I., additional, Shridhar, Ravi, additional, Friedman, Mark, additional, Kim, Richard, additional, El-Haddad, Ghassan, additional, Kis, Bela, additional, Biebel, Benjamin, additional, Sweeney, Jennifer, additional, Choi, Junsung, additional, Anaya, Daniel, additional, Giuliano, Anna R., additional, and Hoffe, Sarah E., additional

Published
2018
Full Text
View/download PDF

145. Adjuvant chemotherapy and outcomes in esophageal carcinoma

Author

Saeed, Nadia A., primary, Mellon, Eric A., additional, Meredith, Kenneth L., additional, Hoffe, Sarah E., additional, Shridhar, Ravi, additional, Frakes, Jessica, additional, Fontaine, Jacque-Pierre, additional, Pimiento, Jose M., additional, Kothari, Nishi, additional, and Almhanna, Khaldoun, additional

Published
2017
Full Text
View/download PDF

147. Impact of sarcopenia on outcomes of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation followed by surgery

Author

Murimwa, Gilbert Z., primary, Venkat, Puja S., additional, Jin, William, additional, Leuthold, Susan, additional, Latifi, Kujtim, additional, Almhanna, Khaldoun, additional, Pimiento, Jose M., additional, Fontaine, Jacques-Pierre, additional, Hoffe, Sarah E., additional, and Frakes, Jessica M., additional

Published
2017
Full Text
View/download PDF

149. Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer

Author

Blackham, Aaron U., primary, H. Naqvi, Syeda M., additional, Schell, Michael J., additional, Jin, William, additional, Gangi, Alexandra, additional, Almhanna, Khaldoun, additional, Fontaine, Jacques P., additional, Hoffe, Sarah E., additional, Frakes, Jessica, additional, Venkat, Puja, additional, and Pimiento, Jose M., additional

Published
2017
Full Text
View/download PDF

150. Fiducial markers coupled with 3D PET/CT offer more accurate radiation treatment delivery for locally advanced esophageal cancer

Author

Oliver, Jasmine, additional, Venkat, Puja, additional, Frakes, Jessica, additional, Klapman, Jason, additional, Harris, Cynthia, additional, Montilla-Soler, Jaime, additional, Dhadham, Gautamy, additional, Altazi, Baderaldeen, additional, Zhang, Geoffrey, additional, Moros, Eduardo, additional, Shridhar, Ravi, additional, Hoffe, Sarah, additional, and Latifi, Kujtim, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results